Comparison · NCT03099382-sae
Camrelizumab vs Investigator's Choice of Standard Therapy: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Camrelizumab vs Investigator's Choice of Standard Therapy: serious adverse events. Trial comparisons, record NCT03099382-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03099382-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.311 | 0.255 | 0.374 | wilson | |
| Risk in group 2 | 0.236 | 0.185 | 0.297 | wilson | |
| Risk difference, group 1 minus group 2 | 0.075 | -0.00768 | 0.156 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.32 | 0.97 | 1.79 | log | |
| Odds ratio, group 1 over group 2 | 1.46 | 0.961 | 2.22 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Camrelizumab than on Investigator's Choice of Standard Therapy | 13.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Camrelizumab | camrelizumab: Subjects received camrelizumab intravenous infusion at the dose 200mg on Day 1 every 2 weeks | 71 | 228 | EG000 |
| Group 2 | Investigator's Choice of Standard Therapy | Docetaxel or Irinotecan~Docetaxel: Subjects received Docetaxel intravenous infusion at the dose 75mg/m2 on Day 1 every 3 weeks~Irinotecan: Subjects received Irinotecan intravenous infusion at the dose 180mg/m2 on Day 1 every 2 weeks | 52 | 220 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- approximately 24 months
Source ClinicalTrials.gov
Trial
- Title
- Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
- NCT number
- NCT03099382
- Phases
- PHASE3
- Conditions
- Esophageal Carcinoma
- Interventions
- camrelizumab, Docetaxel, Irinotecan
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Results first posted
- 2024-01-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03099382?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03099382-sae